spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  anti-CD3 

 HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2023
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Dec 2022
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Jul 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jan 2021
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2020
Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jan 2020
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Nov 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement for Octreotide Long Acting Injectable (LAI) Microsphere for Neuroendocrine Cancers and Acromegaly
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 24 Oct 2019
Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 19 Sep 2019
CASI Pharmaceuticals Announces the Promotion of Larry Zhang to President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jan 2019
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Nov 2016
OrbusNeich Introduces a New Generation COMBO Plus Dual Therapy Stent for Active Healing
Devices Interventional Cardiology Product Launch
 HSMN NewsFeed - 15 Sep 2015
Molecular Response Appoints the Former Head of Translational Medicine Oncology at MedImmune/AstraZeneca, Brett Hall, Ph.D., as Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 31 Oct 2012
Takeda and Millennium Announce European Conditional Marketing Authorization for ADCETRIS(R) (Brentuximab Vedotin)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Mar 2011
Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 9 Feb 2010
Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Dec 2009
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jun 2009
Paulo F. Costa Joins MacroGenics Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Mar 2009
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Mar 2009
MacroGenics Appoints New Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Mar 2009
Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 25 Sep 2008
MacroGenics Raises $25M in Series D-2 Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 May 2008
MacroGenics Appoints New Chief Commercial Officer and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Oct 2007
Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Oct 2007
GlaxoSmithKline and Tolerx Form Worldwide Collaboration for Development and Commercialization of Novel Medication
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2007
Lilly and MacroGenics Announce Licensing and Collaboration Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Feb 2007
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Oct 2006
MacroGenics Receives Orphan Drug Designation From FDA for Monoclonal Antibody to Treat Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
anti-CD3
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!